Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria

in European Journal of Endocrinology

Correspondence should be addressed to G Meyer; Email: Gesine.Meyer@kgu.de
Restricted access

Objective

Hormone treatment is an important part of gender reassignment therapy in gender dysphoria. Previous data about efficacy and safety are commonly based on small cohorts or they comprise former cohorts under meanwhile obsolete therapy regimes. Our objective was to investigate these topics in a large cohort of individuals under guideline-based treatment.

Design/methods

Cohort study of medical files of n = 155 male-to-female (transwomen) and n = 233 female-to-male transgender persons (transmen) of an Endocrine outpatient clinic between 2009 and 2017.

Results

Median time to reach amenorrhoea in transmen under testosterone monotherapy was 3 months, regardless of whether testosterone undecanoat or gel was used. Transmen with higher levels of hemoglobin 3–4 months after onset of GAHT had a greater chance to reach amenorrhea early, whereas testosterone levels showed no significant correlation (hemoglobin: HR: 1.639; 95% CI: 1.036–2.591, P = 0.035; testosterone: HR: 0.999; 95% CI: 0.998–1.001, P = 0.490). Estradiol levels (ρ −0.117; P = 0.316) had no significant influence on breast development in transwomen. Testosterone levels (ρ −0.398; P < 0.001) and FAI (ρ 0.346; P = 0.004) were significantly negatively correlated with reached Tanner stage. Liver values and blood lipids showed an alignment to reference range of the required sex in both groups. Relevant elevations of liver values were rare (2.44% in transmen, 4.23% in transwomen) and transient in most cases. Most relevant side effects were acne (44.8%), respectively erythrocytosis (up to 5.6%) in transmen and venous thrombembolism (1.9%) in transwomen.

Conclusions

Gender-affirming hormone therapy in accordance with current clinical practice guidelines is efficient and safe.

 

     European Society of Endocrinology

All Time Past Year Past 30 Days
Abstract Views 111 111 111
Full Text Views 21 21 21
PDF Downloads 18 18 18
  • 1

    OrentreichNDurrNP. Proceedings: mammogenesis in transsexuals. Journal of Investigative Dermatology 1974 142146. (https://doi.org/10.1111/1523-1747.ep12678272)

    • Search Google Scholar
    • Export Citation
  • 2

    MeyerWJ3rdWebbAStuartCAFinkelsteinJWLawrenceBWalkerPA. Physical and hormonal evaluation of transsexual patients: a longitudinal study. Archives of Sexual Behavior 1986 121138. (https://doi.org/10.1007/bf01542220)

    • Search Google Scholar
    • Export Citation
  • 3

    PelusiCCostantinoAMartelliVLambertiniMBazzocchiAPontiFBattistaGVenturoliSMeriggiolaMC. Effects of three different testosterone formulations in female-to-male transsexual persons. Journal of Sexual Medicine 2014 30023011. (https://doi.org/10.1111/jsm.12698)

    • Search Google Scholar
    • Export Citation
  • 4

    MuellerAHaeberleLZollverHClaassenTKronawitterDOppeltPGCupistiSBeckmannMWDittrichR. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. Journal of Sexual Medicine 2010 31903198. (https://doi.org/10.1111/j.1743-6109.2010.01912.x)

    • Search Google Scholar
    • Export Citation
  • 5

    WiepjesCMNotaNMde BlokCJMKlaverMde VriesALCWensing-KrugerSAde JonghRTBoumanMBSteensmaTDCohen-KettenisP et al. The Amsterdam cohort of gender Dysphoria Study (1972–2015): trends in prevalence, treatment, and regrets. Journal of Sexual Medicine 2018 582590. (https://doi.org/10.1016/j.jsxm.2018.01.016)

    • Search Google Scholar
    • Export Citation
  • 6

    van KesterenPJMAsschemanHMegensJAJGoorenLJG. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology 1997 337342. (https://doi.org/10.1046/j.1365-2265.1997.2601068.x)

    • Search Google Scholar
    • Export Citation
  • 7

    AsschemanHGoorenLJGEklundPLE. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism: Clinical and Experimental 1989 869873. (https://doi.org/10.1016/0026-0495(89)90233-3)

    • Search Google Scholar
    • Export Citation
  • 8

    WierckxKMuellerSWeyersSVan CaenegemERoefGHeylensGT’SjoenG. Long-term evaluation of cross-sex hormone treatment in transsexual persons. Journal of Sexual Medicine 2012 26412651. (https://doi.org/10.1111/j.1743-6109.2012.02876.x)

    • Search Google Scholar
    • Export Citation
  • 9

    GetahunDNashRFlandersWDBairdTCBecerra-CulquiTACromwellLHunkelerELashTLMillmanAQuinnVP et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Annals of Internal Medicine 2018 205213. (https://doi.org/10.7326/M17-2785)

    • Search Google Scholar
    • Export Citation
  • 10

    MooreEWisniewskiADobsA. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. Journal of Clinical Endocrinology and Metabolism 2003 34673473. (https://doi.org/10.1210/jc.2002-021967)

    • Search Google Scholar
    • Export Citation
  • 11

    ElaminMBGarciaMZMuradMHErwinPJMontoriVM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clinical Endocrinology 2010 110. (https://doi.org/10.1111/j.1365-2265.2009.03632.x)

    • Search Google Scholar
    • Export Citation
  • 12

    SealLJ. A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria. Annals of Clinical Biochemistry 2016 1020. (https://doi.org/10.1177/0004563215587763)

    • Search Google Scholar
    • Export Citation
  • 13

    VelhoIFigheraTMZiegelmannPKSpritzerPM. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology 2017 881888. (https://doi.org/10.1111/andr.12382)

    • Search Google Scholar
    • Export Citation
  • 14

    DefreyneJVan de BruaeneLDLRietzschelEVan SchuylenberghJT’SjoenGGR. Effects of gender-affirming hormones on lipid, metabolic, and cardiac surrogate blood markers in transgender persons. Clinical Chemistry 2019 119134. (https://doi.org/10.1373/clinchem.2018.288241)

    • Search Google Scholar
    • Export Citation
  • 15

    GoorenLJGiltayEJ. Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects. Andrologia 2014 570575. (https://doi.org/10.1111/and.12111)

    • Search Google Scholar
    • Export Citation
  • 16

    DeutschMBBhakriVKubicekK. Effects of cross-sex hormone treatment on transgender women and men. Obstetrics and Gynecology 2015 605610. (https://doi.org/10.1097/AOG.0000000000000692)

    • Search Google Scholar
    • Export Citation
  • 17

    GohHHLokeDFMRatnamSS. The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women. Maturitas 1995 6570. (https://doi.org/10.1016/0378-5122(94)00861-z)

    • Search Google Scholar
    • Export Citation
  • 18

    WierckxKVan CaenegemESchreinerTHaraldsenIFisherADToyeKKaufmanJMT’SjoenG. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. Journal of Sexual Medicine 2014 19992011. (https://doi.org/10.1111/jsm.12571)

    • Search Google Scholar
    • Export Citation
  • 19

    ColemanEBocktingWBotzerMCohen-KettenisPCuypereGFeldmanJFraserLGreenJKnudsonGMeyerWJ et al. Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. International Journal of Transgenderism 2012 165232. (https://doi.org/10.1080/15532739.2011.700873)

    • Search Google Scholar
    • Export Citation
  • 20

    HembreeWCCohen-KettenisPDelemarre-van de WaalHAGoorenLJMeyerWJ3rdSpackNPTangprichaVMontoriVM & Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2009 31323154. (https://doi.org/10.1210/jc.2009-0345)

    • Search Google Scholar
    • Export Citation
  • 21

    HembreeWCCohen-KettenisPTGoorenLHannemaSEMeyerWJMuradMHRosenthalSMSaferJDTangprichaVT’SjoenGG. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2017 38693903. (https://doi.org/10.1210/jc.2017-01658)

    • Search Google Scholar
    • Export Citation
  • 22

    De BlokCJMKlaverMWiepjesCMNotaNMHeijboerACFisherADSchreinerTT’SjoenGDen HeijerM. Breast development in transwomen after 1 year of cross-sex hormone therapy: results of a prospective multicenter study. Journal of Clinical Endocrinology and Metabolism 2018 532538. (https://doi.org/10.1210/jc.2017-01927)

    • Search Google Scholar
    • Export Citation
  • 23

    WierckxKGoorenLT’SjoenG. Clinical review: breast development in trans women receiving cross-sex hormones. Journal of Sexual Medicine 2014 12401247. (https://doi.org/10.1111/jsm.12487)

    • Search Google Scholar
    • Export Citation
  • 24

    NotaNMWiepjesCMDe BlokCJMGoorenLJGKreukelsBPCDen HeijerM. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation 2019 14611462. (https://doi.org/10.1161/CIRCULATIONAHA.118.038584)

    • Search Google Scholar
    • Export Citation
  • 25

    MuellerAKiesewetterFBinderHBeckmannMWDittrichR. Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. Journal of Clinical Endocrinology and Metabolism 2007 34703475. (https://doi.org/10.1210/jc.2007-0746)

    • Search Google Scholar
    • Export Citation
  • 26

    DittrichRBinderHCupistiSHoffmannIBeckmannMWMuellerA. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist. Experimental and Clinical Endocrinology and Diabetes 2005 586592. (https://doi.org/10.1055/s-2005-865900)

    • Search Google Scholar
    • Export Citation
  • 27

    GiltayEJGoorenLJG. Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology and Metabolism 2000 29132921. (https://doi.org/10.1210/jcem.85.8.6710)

    • Search Google Scholar
    • Export Citation
  • 28

    WierckxKVan de PeerFVerhaegheEDedeckerDVan CaenegemEToyeKKaufmanJMT’SjoenG. Short- and long-term clinical skin effects of testosterone treatment in trans men. Journal of Sexual Medicine 2014 222229. (https://doi.org/10.1111/jsm.12366)

    • Search Google Scholar
    • Export Citation
  • 29

    DefreyneJVantommeBVan CaenegemEWierckxKDe BlokCJMKlaverMNotaNMVan DijkDWiepjesCMDen HeijerM et al. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the investigation of gender incongruence. Andrology 2018 446454. (https://doi.org/10.1111/andr.12485)

    • Search Google Scholar
    • Export Citation
  • 30

    ArnoldJDSarkodieEPColemanMEGoldsteinDA. Incidence of venous thromboembolism in transgender women receiving oral estradiol. Journal of Sexual Medicine 2016 17731777. (https://doi.org/10.1016/j.jsxm.2016.09.001)

    • Search Google Scholar
    • Export Citation
  • 31

    AsschemanHT’SjoenGLemaireAMasMMeriggiolaMCMuellerAKuhnADhejneCMorel-JournelNGoorenLJ. Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review. Andrologia 2014 791795. (https://doi.org/10.1111/and.12150)

    • Search Google Scholar
    • Export Citation